Acute Stroke and the tPA Dilemma

March 2010
MD Conference Express;Mar2010, p33
Academic Journal
The article offers information on the role of tissue plasminogen activator (tPA) in the treatment of less severe stroke patients. It mentions that proper identification of stroke mimics from stroke is important in the treatment of patients with tPA and it is concluded that the treatment of stroke mimics with tPA carries low risk. It also cites that treatment of complex stroke cases with tPA entails physicians with the challenge of assessing risk versus benefits.


Related Articles

  • Medics dealing with use of t-Pa in strokes. Scott, Lisa // Modern Healthcare;2/12/96, Vol. 26 Issue 7, p108 

    Reports on the risk involved in the use of tissue plasminogen activator (t-Pa) to prevent brain damage in some stroke victims. Importance of time in the administration of t-Pa; Caution from experts regarding the therapy; Risk of intracerebral hemorrhages or death; Handling of strokes as...

  • Could experimental drug stop strokes? Gray, Valerie Lynn // Black Enterprise;May97, Vol. 27 Issue 10, p132 

    Presents information on experimental drug tissue plasminogen activator (TPA) which help stop stroke in progress. Its route of administration; Stroke prevention; Comparison of Blacks with White patients with stroke.

  • Investigation of the causes of clinical symptom aggravation in process of intravenous thrombolysis with alteplase. ZHANG Chen-hao; ZHANG Pei-lan; CHEN Yan; LI Chen-hua; WANG Yu-xin // Chinese Journal of Contemporary Neurology & Neurosurgery;Apr2013, Vol. 13 Issue 4, p297 

    Objective To explore the causes of aggravation of microcirculation disorders in the process of intravenous thrombolysis with alteplase and the clinical outcomes. Methods The clinical data of the aggravated signs and symptoms of 13 cases treated by alteplase were reported, and the onset...

  • Safety of Early Carotid Artery Stenting after Systemic Thrombolysis: A Single Center Experience. Sallustio, Fabrizio; Koch, Giacomo; Rocco, Alessandro; Rossi, Costanza; Pampana, Enrico; Gandini, Roberto; Meschini, Alessandro; Diomedi, Marina; Stanzione, Paolo; Di Legge, Silvia // Stroke Research & Treatment;2012, p1 

    Background. Patients with acute ischemic stroke due to internal carotid artery (ICA) disease are at high risk of early stroke recurrence. A combination of IV thrombolysis and early carotid artery stenting (CAS) may result in more effective secondary stroke prevention. Objective. We tested safety...

  • Definition and Treatment of Rapidly Improving Stroke Symptoms Are Uncertain. Greb, Erik // Neurology Reviews;Apr2014, Vol. 22 Issue 4, p29 

    The article discusses a study led by Pirouz Piran and colleagues, presented at the 2014 International Stroke Conference held as of April 2014, which revealed that there is no accepted definition for rapidly improving stroke symptoms (RISS). It mentions that the researchers reviewed the...

  • A STROKE OF LUCK. Moyer, Lindsay // Nutrition Action Health Letter;Sep2015, Vol. 42 Issue 7, p6 

    The article discusses the importance of calling 9-1-1 emergency number once one experiences vision, speech and weakness problems and not just wait for it to go away, to enable doctors to administer the clot-dissolving drug tPA within the three-hour window and increase its efficacy. Topics...

  • Pharmacological management of acute ischaemic stroke involves thrombolysis with alteplase and the use of a number of supportive interventions.  // Drugs & Therapy Perspectives;Aug2013, Vol. 29 Issue 8, p236 

    Acute ischaemic stroke is a common condition. Drug treatment involves a small window of opportunity for thrombolysis with intravenous alteplase. Other acute supportive drug interventions include insulin, antipyretics and antihypertensives for maintaining normoglycaemia, euthermia and to treat...

  • Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3).  // Journal of Neurology, Neurosurgery & Psychiatry;Apr2008, Vol. 79 Issue 4, p397 

    Background and Purpose: Models are used to adjust for case mix and to stratify treatment allocation in clinical trials and can, if accurate enough, be used to aid decision-making in individual patients. We aimed to validate, in patients assessed within 6 hours of onset, a previously described...

  • Stopping a `brain-attack'.  // Consumer Reports on Health;Feb97, Vol. 9 Issue 2, p19 

    Reports on the approval of the clot-dissolving drug TPA which stands for tissue plasminogen activator (brand name, Activase) for the treatment of thrombotic stroke. Symptoms; Article published in `The Lancet,' June 29, 1996.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics